Highlights from Tuesday and Wednesday (days 3 and 4) from the ACR annual meeting include: the important and impactful abstracts covered by the Rheumatology Roundup session; upadacitinib clinical trials; and the baricitinib CV and VTE safety analysis.
There are many avenues for interdisciplinary collaboration within rheumatology, as our specialty encompasses every organ system and diseases with protean manifestations. The intersection of rheumatology and immunology is well known and has become increasingly important, given the association of autoimmune conditions with many of the primary immunodeficiency syndromes. This intersection was highlighted today at ACR by two excellent abstracts.
I had the honor of delivering the fourth iteration of my talk on technology tools for the office-based rheumatologist at the 2018 ACR annual meeting. Four years ago, the genesis of this session was from the frustration of the archaic technologies we have been using in our medical practices (including user hostile EHRs), compared to the rapid advancing pace of the consumer technologies we use at home.
RheumNow is in Chicago covering the ACR annual meeting. Here are the highlights from Sunday (day one). Be sure to check our complete coverage, including articles, video reports and tweets, at acr18.rheumnow.com.